<DOC>
	<DOCNO>NCT00002823</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know combination chemotherapy give surgery effective surgery alone non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy follow surgery surgery alone treat patient stage I , stage II , stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Compared With No Treatment Following Surgery Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare impact overall survival adjuvant cisplatin either vinca alkaloid etoposide ( without radiotherapy ) vs. adjuvant chemotherapy patient completely resect stage I/II/III non-small cell lung cancer . II . Assess frequency treatment-related death severe toxic effect . III . Describe pattern failure , second malignancy , toxic effect associate treatment regimen . OUTLINE : This randomize , multicenter study . Patients stratify participate institution , type prior surgery , pathologic stage . Each participate center determine combination chemotherapy regimen three cisplatin dos give patient treat center . The treatment group receive cisplatin combine either vindesine , vinblastine , vinorelbine , etoposide every 3-4 week 3-4 course , depend dose cisplatin . The second group receive adjuvant chemotherapy . Treating institution determine prior enter trial patient receive adjuvant radiotherapy : none ; node-positive disease ; N1 disease ; N2 disease ; eligible randomize radiotherapy trial . For patient treatment group , radiotherapy begin 3-4 week last course . Patients follow 6 month , annually . PROJECTED ACCRUAL : A maximum 3,300 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document nonsmall cell lung cancer Any nonsmall cell histology eligible Pathologic stage I/II/III disease completely resect microscopically clear margin within 60 day entry ( 30 day prefer ) PATIENT CHARACTERISTICS : Age : 18 75 Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No clear contraindication chemotherapy No second malignancy except : Nonmelanomatous skin cancer Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior thoracic radiotherapy Surgery : Complete resection require prior entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage III non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>